Pancreatic Disorders & Therapy

Pancreatic Disorders & Therapy
Open Access

ISSN: 2165-7092

+44 1478 350008

Masafumi Suyama

Publications
  • Research Article
    Phase I Clinical Trial of Peptide Vaccination with KIF20A and VEGFR1 Epitope Peptides in Patients with Advanced Pancreatic Cancer
    Author(s): Junko Kato, Akihito Nagahara, Tomohiro Kodani, Yoshie Higashihara, Yuji Matsumura, Taro Osada, Takashi Yoshizawa, Masafumi Suyama and Sumio Watanabe Junko Kato, Akihito Nagahara, Tomohiro Kodani, Yoshie Higashihara, Yuji Matsumura, Taro Osada, Takashi Yoshizawa, Masafumi Suyama and Sumio Watanabe

    We investigated the safety of peptide vaccination with HLA-A2402-restricted KIF20A and VEGFR1 epitope peptides in patients with advanced pancreatic cancer that was refractory to chemotherapy. This was a prospective nonrandomized, single-arm, phase I clinical trial with a fixed 2-mg dose of KIF20A and VEGFR1 peptides for patients with advanced unresectable pancreatic cancer. We determined the HLA genotype of the subjects after enrollment, results of which were held by the evaluative committee and kept from both patients and investigators until completion of the study. The primary endpoint was safety of the peptide vaccination with secondary endpoints being the immunological responses and clinical outcome. We compared study endpoints between the HLA-A*2402-positive and HLA-A*2402- negative groups. KIF20A and VEGFR1 peptides were subcutaneously administered on days 1, 8, 15, and 22 withi.. View More»
    DOI: 10.4172/2165-7092.1000102

    Abstract PDF

Relevant Topics

Top